2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 697

Identification Methods for Axial Spondyloarthritis in American Veterans
Abstract Number: 698

Is It Possible to Identify Psoriasis Patients Who Will Develop Axial Disease? Real Life Data from Psart (Psoriatic Arthritis Registry of Turkey)
Abstract Number: 699

Improving Ankylosing Spondylitis Specific Outcomes at 6 Months Utilising a Novel Self-Management Education Program
Abstract Number: 700

Problems of Untranslatability: Example of Turkish Version of Basdai
Abstract Number: 701

Is Skin Disease More Important to Women or Men in the Assessment of Disease Activity in Psoriatic Arthritis?
Abstract Number: 702

Is Skin Disease More Important to Patients or Physicians in the Assessment of Disease Activity in Psoriatic Arthritis?
Abstract Number: 703

Isotretinoin-Induced Spondilartropathy-Related Symptoms: A Prospective Study
Abstract Number: 704

Is Axial Involvement Underestimated in Patients with Psoriatic Arthritis? Data from the Bepas Cohort
Abstract Number: 705

Sex Differences in Psoriatic Arthritis: Evaluation of a Real-Life Cohort of 2,118 Italian Patients Treated with Methotrexate
Abstract Number: 706

Undifferentiated Spondylarthritis May More Frequent in Japanese
Abstract Number: 707

Change of Enthesial Involvement Under Treatment Was Independent from the Therapeutic Strategy in Patients with Axial Spondyloarthritis within the Scqm Cohort
Abstract Number: 708

Development of an Activity Disease Score in Patients with Uveitis
Abstract Number: 709

Progression of Patients with Non-Radiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Population-Based Cohort Study
Abstract Number: 710

Baseline Characteristics of Early, Delayed, and Non-Responders in a Non-Radiographic Axial Spondyloarthritis Study
Abstract Number: 711

Gender Specific Differences in Ankylosing Spondylitis at Treatment Initiation in Patients Treated with Infliximab or Golimumab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].